scholarly journals Contribution of Religion/spirituality and Major Depressive Disorder to Altruism

2020 ◽  
Author(s):  
Richard Neugebauer ◽  
Priya Wickramaratne ◽  
Connie Svob ◽  
Clayton McClintock ◽  
Marc J. Gameroff ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
High Risk ◽  
Depressive Disorder ◽  
Posttraumatic Growth ◽  
Risk Group ◽  
Statistical Significance ◽  
Positive Association ◽  
High Risk Group ◽  
Self Report ◽  
Major Depressive

Background. In most studies, religiosity and spirituality (R/S) are positively associated with altruism, whereas depression is negatively associated. However, the cross-sectional designs of these studies limit their epidemiological value. We examine the association of R/S and major depressive disorder (MDD) with altruism in a five year longitudinal study nested in a larger prospective study.Methods. Depressed and non-depressed individuals and their first- and second-generation offspring were assessed over several decades. At Year30 after baseline, R/S was measured using participants’ self-report; MDD, by clinical interview. At Year35, participants completed a measure of altruism. Adjusted odds ratios (AOR) were calculated using multivariate logistic regression; statistical significance, set at p<.05. two-tailed.Results. In the overall sample, both R/S and MDD were significantly associated with altruism, AOR 2.52 (95% CI 1.15-5.49) and AOR 2.43 (95% CI 1.05-5.64), respectively; in the High Risk group alone, the corresponding AORs were 4.69 (95% CI 1.39-15.84) and 4.74 (95% CI 1.92-11.72). Among highly R/S people in the High Risk group, the AOR for MDD with altruism was 22.55 (95% CI 1.23-414.60) p<.04; among the remainder, it was 3.12 (95% CI 0.63-15.30), a substantial but non-significant difference.Limitations. Altruism is based on self-report, not observation, hence, vulnerable to bias.Conclusions. MDD’s positive association with elevated altruism concurs with studies of posttraumatic growth in finding developmental growth from adversity. The conditions that foster MDD’s positive association with altruism and the contribution of R/S to this process requires further study.

scholarly journals Reduced serum VGF levels are linked with suicide risk in Chinese Han patients with major depressive disorder

2020 ◽  
Author(s):  
Xingxing Li ◽  
Huifei Ge ◽  
Dongsheng Zhou ◽  
Xiangping Wu ◽  
Gangqiao Qi ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
High Risk ◽  
Depressive Disorder ◽  
Suicide Risk ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Major Depressive

Abstract Background: VGF (nonacronymic) is a neuropeptide that plays an important role in the pathogenesis of major depressive disorder (MDD). However, no studies have yet investigated VGF levels in patients with MDD who are at risk of suicide. The purpose of the present study was to determine whether serum VGF levels are related to suicide risk in patients with MMD.Methods: A total of 107 patients with MDD and 40 normal control participated in the present study. The risk of suicide was assessed using the Nurses Global Assessment of Suicide Risk (NGASR). On this basis, 60 patients were assigned to a high-risk group (NGASR≥9) and 47 were assigned to a low-risk group (NGASR<9). The severity of depression was measured using the 17-item Hamilton Depression Rating Scale (HDRS). Levels of serum VGF were determined using a double antibody sandwich enzyme-linked immunosorbent assay.Results: Serum VGF levels in the high-risk group (883.34±139.67 pg/mL) were significantly lower than in the low-risk group (1020.56±131.76 pg/mL) and in the control group (1107.00±155.38 pg/mL) (F=31.90, p<0.001). In patients with MDD, suicide risk was significantly negatively correlated with VGF levels (r = -0.55, p=0.001). Conclusions: Reduced serum VGF levels are related to risk of suicide in patients with MDD, so VGF may be a biomarker of suicide risk in MDD.

Depression in Children Admitted to Hospital for Orthopaedic Procedures

1981 ◽  
Vol 138 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Javad H. Kashani ◽  
Randy Venzke ◽  
Edward A. Millar
Keyword(s):  
Major Depressive Disorder ◽  
High Risk ◽  
Depressive Disorder ◽  
Emotional Disorders ◽  
Risk Group ◽  
Total Sample ◽  
High Risk Group ◽  
Major Depressive ◽  
Child Patients ◽  
Depressed Children

SummaryOne hundred children between the ages of 7 and 12 admitted to a hospital for orthopaedic procedures were studied to determine the frequency of depression, according to the DSM III diagnostic criteria for major depressive disorder. Of the total sample, 23 showed evidence of depression. Loss of interest or pleasure was the most frequent symptom. Significantly more parents of these depressed children were themselves found to have adjustment or emotional problems. The authors emphasize the importance of paying special attention to this high risk group of child patients because of their propensity to depression and other emotional disorders.

scholarly journals Reduced serum VGF levels are linked with suicide risk in Chinese Han patients with major depressive disorder

2020 ◽  
Author(s):  
chuang wang ◽  
Xingxing Li ◽  
Huifei Ge ◽  
Xiangping Wu ◽  
Gangqiao Qi ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
High Risk ◽  
Depressive Disorder ◽  
Suicide Risk ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Major Depressive

Abstract Background VGF is a neuropeptide that plays an important role in the pathogenesis of major depressive disorder (MDD). However, no studies have yet investigated VGF levels in patients with MDD who are at risk of suicide. The purpose of the present study was to determine whether serum VGF levels are related to suicide risk in patients with MMD. Methods A total of 107 patients with MDD and 40 normal control participated in the present study. The risk of suicide was assessed using the Nurses Global Assessment of Suicide Risk (NGASR). On this basis, 60 patients were assigned to a high-risk group (NGASR≥9) and 47 were assigned to a low-risk group (NGASR<9). The severity of depression was measured using the 17-item Hamilton Depression Rating Scale (HDRS). Levels of serum VGF were determined using a double antibody sandwich enzyme-linked immunosorbent assay. Results Serum VGF levels in the high-risk group (883.34±139.67 pg/mL) were significantly lower than in the low-risk group (1020.56±131.76 pg/mL) and in the control group (1107.00±155.38 pg/mL) (F=31.90, p<0.001). In patients with MDD, suicide risk was significantly negatively correlated with VGF levels (r = -0.55, p=0.001). Conclusions Reduced serum VGF levels are related to risk of suicide in patients with MDD, so VGF may be one key biomarker of suicide risk in MDD.

scholarly journals Reduced serum VGF levels are linked with suicide risk in Chinese Han patients with major depressive disorder

2020 ◽  
Author(s):  
Xingxing Li ◽  
Huifei Ge ◽  
Dongsheng Zhou ◽  
Xiangping Wu ◽  
Gangqiao Qi ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
High Risk ◽  
Depressive Disorder ◽  
Suicide Risk ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Major Depressive

Abstract Background: VGF (nonacronymic) is a neuropeptide that plays an important role in the pathogenesis of major depressive disorder (MDD). However, no studies have yet investigated VGF levels in patients with MDD who are at risk of suicide. The purpose of the present study was to determine whether serum VGF levels are related to suicide risk in patients with MMD.Methods: A total of 107 patients with MDD and 40 normal control participated in the present study. The risk of suicide was assessed using the Nurses Global Assessment of Suicide Risk (NGASR). On this basis, 60 patients were assigned to a high-risk group (NGASR≥9) and 47 were assigned to a low-risk group (NGASR<9). The severity of depression was measured using the 17-item Hamilton Depression Rating Scale (HDRS). Levels of serum VGF were determined using a double antibody sandwich enzyme-linked immunosorbent assay.Results: Serum VGF levels in the high-risk group (883.34±139.67 pg/mL) were significantly lower than in the low-risk group (1020.56±131.76 pg/mL) and in the control group (1107.00±155.38 pg/mL) (F=31.90, p<0.001). In patients with MDD, suicide risk was significantly negatively correlated with VGF levels (r = -0.55, p=0.001). Conclusions: Reduced serum VGF levels are related to risk of suicide in patients with MDD, so VGF may be a biomarker of suicide risk in MDD.

scholarly journals The Symptom Structure of Postdisaster Major Depression: Convergence of Evidence from 11 Disaster Studies Using Consistent Methods

2021 ◽  
Vol 11 (1) ◽  
pp. 8
Author(s):  
Carol S. North ◽  
David Baron
Keyword(s):  
Major Depressive Disorder ◽  
Major Depression ◽  
Depressive Disorder ◽  
Diagnostic Assessment ◽  
Self Report ◽  
Depression Symptoms ◽  
Symptom Scale ◽  
Major Depressive ◽  
Report Symptom ◽  
Symptom Patterns

Agreement has not been achieved across symptom factor studies of major depressive disorder, and no studies have identified characteristic postdisaster depressive symptom structures. This study examined the symptom structure of major depression across two databases of 1181 survivors of 11 disasters studied using consistent research methods and full diagnostic assessment, addressing limitations of prior self-report symptom-scale studies. The sample included 808 directly-exposed survivors of 10 disasters assessed 1–6 months post disaster and 373 employees of 8 organizations affected by the September 11, 2001 terrorist attacks assessed nearly 3 years after the attacks. Consistent symptom patterns identifying postdisaster major depression were not found across the 2 databases, and database factor analyses suggested a cohesive grouping of depression symptoms. In conclusion, this study did not find symptom clusters identifying postdisaster major depression to guide the construction and validation of screeners for this disorder. A full diagnostic assessment for identification of postdisaster major depressive disorder remains necessary.

scholarly journals Critical Predictors for the Early Detection of Conversion From Unipolar Major Depressive Disorder to Bipolar Disorder: Nationwide Population-Based Retrospective Cohort Study (Preprint)

2019 ◽  
Author(s):  
Ya-Han Hu ◽  
Kuanchin Chen ◽  
I-Chiu Chang ◽  
Cheng-Che Shen
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Cohort Study ◽  
High Risk ◽  
Retrospective Cohort ◽  
Risk Group ◽  
Population Based ◽  
Major Depressive ◽  
Risk Stratification Model

BACKGROUND Unipolar major depressive disorder (MDD) and bipolar disorder are two major mood disorders. The two disorders have different treatment strategies and prognoses. However, bipolar disorder may begin with depression and could be diagnosed as MDD in the initial stage, which may later contribute to treatment failure. Previous studies indicated that a high proportion of patients diagnosed with MDD will develop bipolar disorder over time. This kind of hidden bipolar disorder may contribute to the treatment resistance observed in patients with MDD. OBJECTIVE In this population-based study, our aim was to investigate the rate and risk factors of a diagnostic change from unipolar MDD to bipolar disorder during a 10-year follow-up. Furthermore, a risk stratification model was developed for MDD-to-bipolar disorder conversion. METHODS We conducted a retrospective cohort study involving patients who were newly diagnosed with MDD between January 1, 2000, and December 31, 2004, by using the Taiwan National Health Insurance Research Database. All patients with depression were observed until (1) diagnosis of bipolar disorder by a psychiatrist, (2) death, or (3) December 31, 2013. All patients with depression were divided into the following two groups, according to whether bipolar disorder was diagnosed during the follow-up period: converted group and nonconverted group. Six groups of variables within the first 6 months of enrollment, including personal characteristics, physical comorbidities, psychiatric comorbidities, health care usage behaviors, disorder severity, and psychotropic use, were extracted and were included in a classification and regression tree (CART) analysis to generate a risk stratification model for MDD-to-bipolar disorder conversion. RESULTS Our study enrolled 2820 patients with MDD. During the follow-up period, 536 patients were diagnosed with bipolar disorder (conversion rate=19.0%). The CART method identified five variables (kinds of antipsychotics used within the first 6 months of enrollment, kinds of antidepressants used within the first 6 months of enrollment, total psychiatric outpatient visits, kinds of benzodiazepines used within one visit, and use of mood stabilizers) as significant predictors of the risk of bipolar disorder conversion. This risk CART was able to stratify patients into high-, medium-, and low-risk groups with regard to bipolar disorder conversion. In the high-risk group, 61.5%-100% of patients with depression eventually developed bipolar disorder. On the other hand, in the low-risk group, only 6.4%-14.3% of patients with depression developed bipolar disorder. CONCLUSIONS The CART method identified five variables as significant predictors of bipolar disorder conversion. In a simple two- to four-step process, these variables permit the identification of patients with low, intermediate, or high risk of bipolar disorder conversion. The developed model can be applied to routine clinical practice for the early diagnosis of bipolar disorder.

The Effect of Desipramine upon Central Adrenergic Function in Depressed Patients

1982 ◽  
Vol 141 (4) ◽  
pp. 372-376 ◽  
Author(s):  
Ilana B. Glass ◽  
Stuart A. Checkley ◽  
Eric Shur ◽  
Sheila Dawling
Keyword(s):  
Growth Hormone ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Diagnostic Criteria ◽  
Statistical Significance ◽  
Adaptive Change ◽  
The Other ◽  
Major Depressive ◽  
Uptake Of Noradrenaline ◽  
Drug Free

SummaryEleven drug free patients meeting Research Diagnostic Criteria for Major Depressive Disorder have been treated with desipramine and given a clonidine infusion after 0, 1 and 3 weeks of treatment. The sedative and hypotensive effects of clonidine were significantly inhibited after three weeks of treatment with desipramine: a similar interaction was seen after one week of treatment although this just failed to reach statistical significance. The growth hormone (GH) response to clonidine was initially impaired, but increased significantly after one week of treatment. A significant reduction in the GH response occurred during the second and third weeks of treatment with desipramine. This last finding is interpreted as evidence of adaptive change of α2 adrenoceptors: the other changes can be explained by the known ability of desipramine to block the re-uptake of noradrenaline.

Cognitive Therapy for Major Depressive Disorder in Primary Care

1984 ◽  
Vol 144 (4) ◽  
pp. 400-406 ◽  
Author(s):  
John D. Teasdale ◽  
Melanie J. V. Fennell ◽  
George A. Hibbert ◽  
Peter L Amies
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Therapy ◽  
Comparison Group ◽  
Psychological Treatment ◽  
Antidepressant Medication ◽  
Self Report ◽  
Major Depressive ◽  
Treatment As Usual ◽  
Severity Of Depression

SummaryCognitive therapy for depression is a psychological treatment designed to train patients to identify and correct the negative depressive thinking which, it has been hypothesised, contributes to the maintenance of depression. General practice patients meeting Research Diagnostic Criteria for primary major depressive disorder were randomly allocated either to continue with the treatment they would normally receive (which in the majority of cases included antidepressant medication) or to receive, in addition, sessions of cognitive therapy. At completion of treatment, patients receiving cognitive therapy were significantly less depressed than the comparison group, both on blind ratings of symptom severity made by psychiatric assessors and on a self-report measure of severity of depression. At three-month follow-up cognitive therapy patients no longer differed from patients receiving treatment-as-usual, but this was mainly as a result of continuing improvement in the comparison group.

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

2020 ◽  
pp. 026988112095404
Author(s):  
Roger S McIntyre ◽  
Nelson B Rodrigues ◽  
Orly Lipsitz ◽  
Flora Nasri ◽  
Hartej Gill ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Depressive Symptomatology ◽  
Rapid Onset ◽  
Anxiety Symptoms ◽  
Self Report ◽  
Treatment Center ◽  
Treatment Resistant ◽  
Major Depressive

Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms. Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress. Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic.Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR16) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR16 total score, QIDS-SR16 suicidal ideation (SI) item and GAD7 score were analyzed between groups. Results: A total of 209 adults with MDD ( n = 177) and BD ( n = 26) were included in this analysis. From this sample, 94 patients (mean = 45 ± 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR16 total score following four infusions ( p = 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI ( p < 0.0001) following four infusions.Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non–anxious distress group following three ( p = 0.02) and four infusions ( p < 0.001). Conclusion: Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms.

Sign in / Sign up

Export Citation Format

Share Document